| [1] |
Kolbeinsson HM, Chandana S, Wright GP, et al. Pancreatic cancer: a review of current treatment and novel therapies[J]. J Invest Surg, 2023, 36(1): 2129884. DOI: 10.1080/08941939.2022.2129884.
|
| [2] |
Groot VP, Gemenetzis G, Blair AB, et al. Defining and predicting early recurrence in 957 patients with resected pancreatic ductal adenocarcinoma[J]. Ann Surg, 2019, 269(6): 1154-1162. DOI: 10.1097/SLA.0000000000002734.
|
| [3] |
Chen PT, Wu T, Wang P, et al. Pancreatic cancer detection on CT scans with deep learning: a nationwide population-based study[J]. Radiology, 2023, 306(1): 172-182. DOI: 10.1148/radiol.220152.
|
| [4] |
|
| [5] |
Luo G, Jin K, Deng S, et al. Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter[J]. Biochim Biophys Acta Rev Cancer, 2021, 1875(2): 188409. DOI: 10.1016/j.bbcan.2020.188409.
|
| [6] |
Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility[J]. J Clin Invest, 2022, 132(12): e154941. DOI: 10.1172/JCI154941.
|
| [7] |
Pietrasz D, Sereni E, Lancelotti F, et al. Circulating tumour DNA: a challenging innovation to develop “precision onco-surgery” in pancreatic adenocarcinoma[J]. Br J Cancer, 2022, 126(12): 1676-1683. DOI: 10.1038/s41416-022-01745-2.
|
| [8] |
Ueberroth BE, Jones JC, Bekaii-Saab TS. Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma[J]. Pancreatology, 2022, 22(6): 741-748. DOI: 10.1016/j.pan.2022.06.009.
|
| [9] |
Dennis Lo YM, Han DSC, Jiang P, et al. Epigenetics, fragmentomics, and topology of cell-free DNA in liquid biopsies[J]. Science, 2021, 372(6538): eaaw3616. DOI: 10.1126/science.aaw3616.
|
| [10] |
|
| [11] |
Swietlik JJ, Bärthel S, Falcomatà C, et al. Cell-selective proteomics segregates pancreatic cancer subtypes by extracellular proteins in tumors and circulation[J]. Nat Commun, 2023, 14(1): 2642. DOI: 10.1038/s41467-023-38171-8.
|
| [12] |
Adamo P, Cowley CM, Neal CP, et al. Profiling tumour heterogeneity through circulating tumour DNA in patients with pancreatic cancer[J]. Oncotarget, 2017, 8(50): 87221-87233. DOI: 10.18632/oncotarget.20250.
|
| [13] |
Wu J, Xu X, Zhang Q, et al. Cell-free DNA testing for the detection and prognosis prediction of pancreatic cancer[J]. Nat Commun, 2025, 16(1): 6645. DOI: 10.1038/s41467-025-61890-z.
|
| [14] |
中国医师协会临床精准医疗专业委员会, 中国抗癌协会肿瘤胰腺病学专业委员会. 早期胰腺癌分子诊断专家共识(2023年版)[J]. 临床肝胆病杂志, 2024, 40(3): 473-477. DOI: 10.12449/JCH240306. |
| [15] |
Marin AM, Batista M, de Azevedo ALK, et al. Screening of exosome-derived proteins and their potential as biomarkers in diagnostic and prognostic for pancreatic cancer[J]. Int J Mol Sci, 2023, 24(16): 12604. DOI: 10.3390/ijms241612604.
|
| [16] |
Wu J, Zhou Y, Zhang CY, et al. Co-amplification at lower denaturation-temperature PCR combined with unlabled-probe high-resolution melting to detect KRAS codon 12 and 13 mutations in plasma-circulating DNA of pancreatic adenocarcinoma cases[J]. Asian Pac J Cancer Prev, 2014, 15(24): 10647-10652. DOI: 10.7314/apjcp.2014.15.24.10647.
|
| [17] |
Cohen JD, Javed AA, Thoburn C, et al. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers[J]. Proc Natl Acad Sci USA, 2017, 114(38): 10202-10207. DOI: 10.1073/pnas.1704961114.
|
| [18] |
Hálková T, Bunganič B, Traboulsi E, et al. Prognostic role of specific KRAS mutations detected in aspiration and liquid biopsies from patients with pancreatic cancer[J]. Genes, 2024, 15(10): 1302. DOI: 10.3390/genes15101302.
|
| [19] |
Gao Q, Lin YP, Li BS, et al. Unintrusive multi-cancer detection by circulating cell-free DNA methylation sequencing (THUNDER): development and independent validation studies[J]. Ann Oncol, 2023, 34(5): 486-495. DOI: 10.1016/j.annonc.2023.02.010.
|
| [20] |
Okada T, Mizukami Y, Ono Y, et al. Digital PCR-based plasma cell-free DNA mutation analysis for early-stage pancreatic tumor diagnosis and surveillance[J]. J Gastroenterol, 2020, 55(12): 1183-1193. DOI: 10.1007/s00535-020-01724-5.
|
| [21] |
Gandara DR, Agarwal N, Gupta S, et al. Tumor mutational burden and survival on immune checkpoint inhibition in > 8000 patients across 24 cancer types[J]. J Immunother Cancer, 2025, 13(2): e010311. DOI: 10.1136/jitc-2024-010311.
|
| [22] |
Lawlor RT, Mattiolo P, Mafficini A, et al. Tumor mutational burden as a potential biomarker for immunotherapy in pancreatic cancer: systematic review and still-open questions[J]. Cancers, 2021, 13(13): 3119. DOI: 10.3390/cancers13133119.
|
| [23] |
Tang R, Liu X, Wang W, et al. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma[J]. Cancer Cell Int, 2021, 21(1): 196. DOI: 10.1186/s12935-021-01900-4.
|
| [24] |
Pratt ED, Cowan RW, Manning SL, et al. Multiplex enrichment and detection of rare KRAS mutations in liquid biopsy samples using digital droplet pre-amplification[J]. Anal Chem, 2019, 91(12): 7516-7523.
|
| [25] |
Herreros-Villanueva M, Bujanda L, Ruiz-Rebollo L, et al. Circulating tumor DNA tracking in patients with pancreatic cancer using next-generation sequencing[J]. Gastroenterol Hepatol, 2022, 45(8): 637-644. DOI: 10.1016/j.gastrohep.2021.12.011.
|
| [26] |
Takai E, Totoki Y, Nakamura H, et al. Clinical utility of circulating tumor DNA for molecular assessment and precision medicine in pancreatic cancer[J]. Adv Exp Med Biol, 2016, 924: 13-17. DOI: 10.1007/978-3-319-42044-8_3.
|
| [27] |
Park G, Park JK, Son DS, et al. Utility of targeted deep sequencing for detecting circulating tumor DNA in pancreatic cancer patients[J]. Sci Rep, 2018, 8(1): 11631. DOI: 10.1038/s41598-018-30100-w.
|
| [28] |
Freed IM, Kasi A, Fateru O, et al. Circulating tumor cell subpopulations predict treatment outcome in pancreatic ductal adenocarcinoma (PDAC) patients[J]. Cells, 2023, 12(18): 2266. DOI: 10.3390/cells12182266.
|
| [29] |
Hou J, Li X, Xie KP. Coupled liquid biopsy and bioinformatics for pancreatic cancer early detection and precision prognostication[J]. Mol Cancer, 2021, 20(1): 34. DOI: 10.1186/s12943-021-01309-7.
|
| [30] |
Henriksen SD, Stubbe BE, Madsen PH, et al. Cell-free DNA promoter hypermethylation as a diagnostic marker for pancreatic ductal adenocarcinoma-An external validation study[J]. Pancreatology, 2021, 21(6): 1081-1091. DOI: 10.1016/j.pan.2021.05.003.
|
| [31] |
Yi JM, Guzzetta AA, Bailey VJ, et al. Novel methylation biomarker panel for the early detection of pancreatic cancer[J]. Clin Cancer Res, 2013, 19(23): 6544-6555. DOI: 10.1158/1078-0432.CCR-12-3224.
|
| [32] |
Eissa MAL, Lerner L, Abdelfatah E, et al. Promoter methylation of ADAMTS1 and BNC1 as potential biomarkers for early detection of pancreatic cancer in blood[J]. Clin Epigenetics, 2019, 11(1): 59. DOI: 10.1186/s13148-019-0650-0.
|
| [33] |
Li S, Wang L, Zhao Q, et al. Genome-wide analysis of cell-free DNA methylation profiling for the early diagnosis of pancreatic cancer[J]. Front Genet, 2020, 11: 596078. DOI: 10.3389/fgene.2020.596078.
|
| [34] |
Shinjo K, Hara K, Nagae G, et al. A novel sensitive detection method for DNA methylation in circulating free DNA of pancreatic cancer[J]. PLoS One, 2020, 15(6): e0233782. DOI: 10.1371/journal.pone.0233782.
|
| [35] |
Zhao G, Jiang R, Shi Y, et al. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma[J]. Mol Oncol, 2024, 18(11): 2801-2813. DOI: 10.1002/1878-0261.13643.
|
| [36] |
Wu H, Guo S, Liu X, et al. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA[J]. BMC Med, 2022, 20(1): 458. DOI: 10.1186/s12916-022-02647-z.
|
| [37] |
Miller BF, Petrykowska HM, Elnitski L. Assessing ZNF154 methylation in patient plasma as a multicancer marker in liquid biopsies from colon, liver, ovarian and pancreatic cancer patients[J]. Sci Rep, 2021, 11(1): 221. DOI: 10.1038/s41598-020-80345-7.
|
| [38] |
Mouliere F, Chandrananda D, Piskorz AM, et al. Enhanced detection of circulating tumor DNA by fragment size analysis[J]. Sci Transl Med, 2018, 10(466): eaat4921. DOI: 10.1126/scitranslmed.aat4921.
|
| [39] |
Bardol T, Dujon AM, Taly V, et al. Early detection of pancreatic cancer by liquid biopsy “PANLIPSY”: a French nation-wide study project[J]. BMC Cancer, 2024, 24(1): 709. DOI: 10.1186/s12885-024-12463-8.
|
| [40] |
Liu X, Liu L, Ji Y, et al. Enrichment of short mutant cell-free DNA fragments enhanced detection of pancreatic cancer[J]. EBioMedicine, 2019, 41: 345-356. DOI: 10.1016/j.ebiom.2019.02.010.
|
| [41] |
Cristiano S, Leal A, Phallen J, et al. Genome-wide cell-free DNA fragmentation in patients with cancer[J]. Nature, 2019, 570(7761): 385-389. DOI: 10.1038/s41586-019-1272-6.
|
| [42] |
Zvereva M, Roberti G, Durand G, et al. Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA[J]. EBioMedicine, 2020, 55: 102462. DOI: 10.1016/j.ebiom.2019.09.042.
|
| [43] |
Steele CD, Abbasi A, Ashiqul Islam SM, et al. Signatures of copy number alterations in human cancer[J]. Nature, 2022, 606(7916): 984-991. DOI: 10.1038/s41586-022-04738-6.
|
| [44] |
Douville C, Springer S, Kinde I, et al. Detection of aneuploidy in patients with cancer through amplification of long interspersed nucleotide elements (LINEs)[J]. Proc Natl Acad Sci U S A, 2018, 115(8): 1871-1876. DOI: 10.1073/pnas.1717846115.
|
| [45] |
Douville C, Cohen JD, Ptak J, et al. Assessing aneuploidy with repetitive element sequencing[J]. Proc Natl Acad Sci U S A, 2020, 117(9): 4858-4863. DOI: 10.1073/pnas.1910041117.
|
| [46] |
Ben-Ami R, Wang QL, Zhang J, et al. Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer[J]. Gut, 2024, 73(4): 639-648. DOI: 10.1136/gutjnl-2023-331074.
|
| [47] |
Yin L, Cao C, Lin J, et al. Development and validation of a cell-free DNA fragmentomics-based model for early detection of pancreatic cancer[J]. J Clin Oncol, 2025, 43(26): 2863-2874. DOI: 10.1200/JCO.24.00287.
|